At a CAGR of 9.1% Sepsis Diagnostics Market expected to reach $613.9 million by 2023

Increasing geriatric population, growing government initiatives for creating sepsis awareness, and high incidence of hospital-acquired infections are expected to drive the demand for sepsis diagnosis.

The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis across the globe. Factors such as the growing number of surgical procedures, influx of novel sepsis diagnostic products, high incidence of hospital-acquired infections, funding for sepsis-related research activities, and the commercialization and availability of a wide variety of approved sepsis diagnostic devices are also supporting the growth of this market.

What the Market Looks Like?

Predicted to grow at a CAGR of 9.1 % during the forecast period, the global Sepsis Diagnostics Market is estimated to reach USD 613.9 million by the end of 2023. Asia Pacific is expected to grow at the highest CAGR in the molecular sepsis diagnostics market during the forecast period.

Based on technology, the global sepsis diagnostics market is segmented into— microbiology, molecular diagnostics, immunoassay, flow cytometry, microfluidics, and biomarkers. The biomarkers segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to various advantages offered by this technique in the diagnosis of sepsis and growing need for early disease diagnosis.

Based on products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software. In 2018, the blood culture media segment accounted for the largest share of the market owing to the increased used of blood culture media as it is the standard method for diagnosis of sepsis across the globe.

Based on blood culture media segment commanded the largest share of the global sepsis diagnostics market in 2018. The large share of this segment can be attributed to the increasing use of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis

Based on basis of methods, the sepsis diagnostics market is categorized into two segments, namely, conventional diagnostics and automated diagnostics. The automated diagnostics segment is expected to grow at the highest CAGR from 2018 to 2023. Accurate detection of positive blood cultures, quick turnaround time, and reduced risk of contamination is contributing to the growth of this segment

Please provide your specific interest in this report so as to help you better, Download PDF Brochure @

What Drives the Market?

The growth of the global market for Sepsis Diagnostics is primarily influenced by the following factors:

  • High Incidence of Sepsis in the Adult Population
  • Increasing Incidence of Sepsis in Neonates
  • Growing Incidence of Hospital-Acquired Infections
  • Increasing Number of Surgical Procedures
  • Increasing Burden of Pneumonia
  • Influx of Novel Sepsis Diagnostic Products
  • Rising Initiatives to Increase the Awareness and Drive the Adoption of Sepsis Diagnostic Tests
  • Funding for Sepsis-Related Research Activities

We can help with your specific research requirement for this market. Please share your specific interest to help us serve you better, Request for Sample Pages :

Geographical growth scenario of Sepsis Diagnostics Market

Geographically,  sepsis diagnostic market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific is expected register highest growth during the forecast period, owing to the growing prevalence of sepsis in APAC countries, rising focus of global players in this region, developing healthcare infrastructure, and rising government support for sepsis-related research.

Leading market players and strategies adopted

The prominent players in the Sepsis Diagnostics market include  bioMérieux (France), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), Abbott (US), Roche (Switzerland), Danaher (US), Becton, Dickinson, and Company (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), CytoSorbents (US), and Mitsubishi Chemical Europe (Germany), among others.

Please share your specific interest to serve you better, Request for Bundle Reports @

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact Us:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Visit Our Website:

error: Content is protected !!